These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27194194)

  • 1. The emerging therapeutic roles of κ-opioid agonists.
    Jones MR; Kaye AD; Kaye AJ; Urman RD
    J Opioid Manag; 2016; 12(2):101-7. PubMed ID: 27194194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral kappa-opioid agonists for visceral pain.
    Rivière PJ
    Br J Pharmacol; 2004 Apr; 141(8):1331-4. PubMed ID: 15051626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
    Gallantine EL; Meert TF
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta and kappa opioid receptors as suitable drug targets for pain.
    Vanderah TW
    Clin J Pain; 2010 Jan; 26 Suppl 10():S10-5. PubMed ID: 20026960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?
    Albert-Vartanian A; Boyd MR; Hall AL; Morgado SJ; Nguyen E; Nguyen VP; Patel SP; Russo LJ; Shao AJ; Raffa RB
    J Clin Pharm Ther; 2016 Aug; 41(4):371-82. PubMed ID: 27245498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of current opioid drugs focusing on MOR-related strategies.
    Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
    Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa opioids and the modulation of pain.
    Kivell B; Prisinzano TE
    Psychopharmacology (Berl); 2010 Jun; 210(2):109-19. PubMed ID: 20372880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.
    Simonson B; Morani AS; Ewald AW; Walker L; Kumar N; Simpson D; Miller JH; Prisinzano TE; Kivell BM
    Br J Pharmacol; 2015 Jan; 172(2):515-31. PubMed ID: 24641310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
    Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of kappa-opioid receptor activation in mediating antinociception and addiction.
    Wang YH; Sun JF; Tao YM; Chi ZQ; Liu JG
    Acta Pharmacol Sin; 2010 Sep; 31(9):1065-70. PubMed ID: 20729876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans.
    Machelska H; Pflüger M; Weber W; Piranvisseh-Völk M; Daubert JD; Dehaven R; Stein C
    J Pharmacol Exp Ther; 1999 Jul; 290(1):354-61. PubMed ID: 10381799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
    Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
    J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats.
    Beck TC; Reichel CM; Helke KL; Bhadsavle SS; Dix TA
    Eur J Pharmacol; 2019 Aug; 856():172396. PubMed ID: 31103632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects.
    Santino F; Gentilucci L
    Molecules; 2023 Jan; 28(1):. PubMed ID: 36615540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biased Opioid Receptor Ligands: Gain without Pain.
    Ranjan R; Pandey S; Shukla AK
    Trends Endocrinol Metab; 2017 Apr; 28(4):247-249. PubMed ID: 28110810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.